Valuation Trading Multiples & Precedent Transactions: Genomics Tools and Precision Diagnostics Companies
Valuation benchmarks for Genomics Tools and Precision Diagnostics Companies. Access public trading comps, EV/EBITDA acquisition multiples, and private market data for pitch books and valuation analysis.
1.1 - Genomics Tools and Precision Diagnostics Companies Market Context & Valuation Drivers
Companies in this public trading comparables group develop and commercialize genomics tools and precision oncology diagnostics. Business models span CLIA/FDA-approved liquid biopsy assays, comprehensive genomic profiling, synthetic DNA manufacturing, and outsourced sequencing and biobanking services. They are comparable as valuation benchmarks given shared exposure to NGS workflows, recurring consumables and services revenue, payer/provider adoption cycles, and biopharma research demand.
Typical capabilities include liquid biopsy testing for mutation detection and MRD monitoring, tumor-informed assays and comprehensive genomic profiling, high-throughput gene synthesis and oligonucleotide production, targeted NGS enrichment kits, end-to-end sequencing and bioinformatics, cryogenic biobanking and sample tracking, and laboratory automation for sample management. Revenue models combine per-test fees, project-based services, reagent and consumables sales, and long-term storage contracts. Many also offer informatics subscriptions, secure data reporting portals, and integration with clinical decision-support systems.
Primary customers include oncology providers and health systems adopting precision diagnostics, biopharma and biotech R&D teams, and academic research institutions. Key valuation drivers are revenue growth from test volumes and consumables utilization, gross margin expansion via scale and mix, recurring services and storage contracts, and payer coverage and reimbursement milestones. Metrics such as ASPs, sample throughput, customer retention, and backlog provide comparable benchmarks across public trading comps.
2. Valuation Analysis: Public Trading Comps & Multiples for Genomics Tools and Precision Diagnostics Companies companies
2.1 - Public Peer Groups & Median Valuation Multiples for Genomics Tools and Precision Diagnostics Companies sector
Comparable group 1: Genomics Tools and Precision Diagnostics Companies
Guardant Health
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of blood and tissue tests, data sets, and analytics with a focus on the treatment and management of cancer through precision oncology and advanced research platforms.
- Key Products:
- Guardant360 CDx Test: FDA-approved liquid biopsy test for identifying patients with specific gene mutations to guide treatment decisions
- GuardantOMNI: Liquid biopsy test for comprehensive genomic profiling of tumors in cancer patients
- Shield Test: Blood-based test for colorectal cancer screening
- Guardant Reveal: Blood-only liquid biopsy test for detecting residual and recurrent colorectal cancer
- GuardantINFINITY: High-definition liquid biopsy test for advanced-stage solid tumors.
Twist Bioscience
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of synthetic DNA and genomics products using a proprietary semiconductor-based platform to offer high-throughput DNA synthesis for applications in therapeutics, diagnostics, agriculture, chemicals, and data storage.
- Key Products:
- Gene synthesis: High-throughput silicon-based platform to produce custom genes rapidly and accurately
- Oligo pools: Large-scale production of oligonucleotides for high-throughput screening
- NGS target enrichment: Tools for targeted next-generation sequencing
- Variant libraries: Diverse libraries for accelerated drug discovery
- Biopharma solutions: Antibody discovery and optimization services.